Skip to main content
OpenTrials
Completed

NCT Number: NCT06758856

Effect of Betaine and Choline on Metabolic Health

The purpose of this research is to determine whether extra betaine and choline influence metabolic health in adults with overweight and obesity.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Human Nutraceutical Research Unit

Guelph, Ontario, N1G 2W1, Canada

About this study

Betaine (N,N,N-trimethylglycine or also glycine betaine) is a derivative of choline that functions as an organic osmolyte and participates in one-carbon metabolism as a methyl donor. Betaine is naturally found in beets, wheat and spinach and sold as a food supplement without prescription. Choline is recognized as an essential nutrient that is found in various foods including eggs, nuts and beef, with the major form of choline in food found as phosphatidylcholine. In addition to being oxidized to the methyl donor betaine, choline is a precursor of several compounds involved in neurotransmitter synthesis, lipid metabolism and transport as well as the structural integrity and signaling of cell membranes. Previous studies have reported alterations in one-carbon metabolites in response to a single meal containing different forms of choline, with interindividual variability dependent on genetics and gut microbiota composition. This study will extend to longer-term impact of different forms of choline (betaine as oxidized choline and choline provided from food) with a focus on overweight and obesity, which comprise a predominant portion of the population in North America. The objective of this study is to determine the effect of betaine supplementation with or without food-form choline (eggs) on metabolic health in adults with overweight and obesity. A randomized crossover study design will be employed, which men and women of age 18-70 years with BMI 25-35 kg/m2 will participate in a 14-week study consisting of three 4-week dietary periods: 1) daily consumption of 3 grams of betaine supplement with no eggs; 2) daily consumption of 3 grams of betaine supplement with 3 whole eggs; and 3) daily consumption of 3 grams of cellulose supplement with no eggs, in a random order, each dietary period separated by a 1-week washout break. Blood, urine and fecal samples as well as anthropometric measurements will be collected at baseline, then at weeks 4, 9 and 14. The collected biological samples will be used to measure glucose and lipid markers, one-carbon metabolites and profiling of gut microbiota and genotype to determine interindividual differences in metabolism.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female participant of any race or ethnicity between 18-70 years of age (inclusive) at the time of informed consent
  • BMI between 25-35 kg/m2
  • Non-smoker
  • Willing to consume 3 eggs per day for one dietary period of 4 weeks
  • Willing to avoid eggs during the rest of the study including washout period breaks except for eggs that are provided
  • Willing to fast before the baseline and dietary period lab visits
  • Willing to provide a 24-hr prior day food record at the dietary period lab visits
  • Willing to provide or collect biological specimen samples at the baseline and dietary period lab visits
  • Willing to follow the study protocol including maintaining usual lifestyle during the entire study

Exclusion criteria

  • Male or female < 18 years or > 70 years of age at the time of consent
  • BMI < 25 kg/m2; or BMI > 35 kg/m2
  • Pregnant or planning to become pregnant during the course of the study; currently breastfeeding or postpartum < 6 months
  • Use of hormone therapy including birth control pills
  • Follows a vegan diet
  • Current smoker (any form of nicotine, e-cigarettes, etc)
  • Use of recreational drugs (may affect metabolic pathway for choline)
  • Presence of chronic illnesses, e.g., heart disease, diabetes, cancer, celiac disease, inflammatory bowel disease (Crohn's disease and ulcerative colitis), gastrointestinal liver or kidney diseases or alcoholism
  • Diagnosis of trimethylaminuria (genetic disorder affecting choline use in body)
  • Use of antibiotics in the last 2 months
  • Use of prebiotics, probiotics or dietary fiber (i.e., Metamucil) supplements in the last 2 months
  • Have allergies to eggs or any anaphylactic food allergies
  • Have a schedule or lifestyle patterns incompatible with the study protocol

Treatment and study plan

Trimethylglycine

Dietary Supplement

Betaine anhydrous from sugar beets

Eggs

Other

3 whole eggs

Cellulose

Dietary Supplement

Cellulose

Primary outcomes

  1. Lipid panel

    Time frame: Weeks 0, 4, 9 and 14

    Triglyceride, cholesterol and lipoprotein concentrations

  2. Glucose concentrations

    Time frame: Weeks 0, 4, 9 and 14

    Concentrations of glucose as mol units per volume

  3. Insulin concentrations

    Time frame: Weeks 0, 4, 9 and 14

    Concentrations of insulin as international units per volume

  4. Concentrations of glucose metabolism panel

    Time frame: Weeks 0, 4, 9 and 14

    Concentrations of C-peptide, GLP-1 and GIP as mol units per volume

  5. Body mass

    Time frame: Weeks 0, 4, 9 and 14

    Mass on a scale

  6. One-carbon metabolism panel

    Time frame: Weeks 0, 4, 9 and 14

    Choline metabolite concentrations

Secondary outcomes

  1. Gene expression

    Time frame: Weeks 0, 4, 9 and 14

    Global gene expression in isolated immune cells

  2. Inflammatory response in immune cells

    Time frame: Weeks 0, 4, 9 and 14

    Expression of cytokines in immune cells as assessed in response to lipopolysaccharide challenge

  3. Composition of the gut microbiota

    Time frame: Weeks 0, 4, 9 and 14

    Gut microbiota profiles as assessed by sequencing technologies

  4. Characterization of single nucleotide polymoprhisms

    Time frame: Week 0

    Allelic discrimination of variants in enzymes that influence choline metabolites

  5. Liver health panel

    Time frame: Weeks 0, 4, 9 and 14

    ALT, AST, GGT, ALP and bilirubin concentrations

  6. Blood cell counts

    Time frame: Weeks 0, 4, 9 and 14

    Complete counts of white blood cell, red blood cell, hemoglobin, hematocrit and platelet

  7. Blood pressure

    Time frame: Weeks 0, 4, 9 and 14

    Systolic and diastolic blood pressure

  8. Dietary intake

    Time frame: Weeks 0, 4, 9 and 14

    24-hour prior day food record

Sponsors and collaborators

Lead sponsor

University of Guelph

Other

Registry information

Official study title

ABC (Additional Betaine and Choline) Study: Effect of Betaine and Choline Intake on Biomarkers of Metabolic Health in Humans

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jan 6, 2025
Registry last updated
May 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.